Kaya M G, Alanli R, Kucukay M B, Ulukaya F B, Bakir F
Lokman Hekim University, Faculty of Medicine, Ankara Hospital, Department of Endocrinology and Metabolism, Ankara, Turkey.
Lokman Hekim University, Faculty of Medicine, Ankara Hospital, Department of Internal Diseases, Ankara, Turkey.
Acta Endocrinol (Buchar). 2023 Jul-Sep;19(3):314-318. doi: 10.4183/aeb.2023.314. Epub 2024 Feb 1.
Injury and functional disorders in pituitary gland after COVID-19 still need elucidation.
To investigate pituitary functions, particularly hypothalamic pituitary adrenal (HPA) axis after COVID-19 infection.
This study was conducted at a university hospital between May and October 2021. Patients who had COVID-19, were enrolled as study group, three months after recovery. Participants who do not have COVID-19 diagnosis, with similar characteristics were included as control group. Blood samples were taken on the morning at 08 AM. Adrenal stimulation test was performed with 1 µg of ACTH (Synacthen).
The study group included 50 patients and control group was 49 cases. One (2%) out of the 50 patients with 8 a.m. serum cortisol below 5 µg/dL. Low serum ACTH levels were detected in 7 (14%) participants in patient group. Stimulation with 1 µg of ACTH (Synacthen) test was performed for 2 (4%) of 50 patients with serum cortisol below 10 µg/dL. Both patients achieved a peak cortisol of over 12.5 µg/dL after stimulation. Standard deviation (SD) score for insulin like growh factor-1 (IGF-1) was lower than -2 SD for age and gender in 7 (14%) patients. TSH levels was mildly increased in five (10%) patients. There was no significant difference in baseline pituitary hormone levels in study and control groups.
Basal pituitary hormone levels and HPA axes were found to be preserved and competently functioning in patients who experienced mild/moderate COVID-19. However, symptoms observed after COVID-19 episode were evident in substantial amount of patients in this study and these symptoms were not associated with changes in pituitary gland function.
新冠病毒感染后垂体的损伤和功能障碍仍需阐明。
研究新冠病毒感染后垂体功能,尤其是下丘脑 - 垂体 - 肾上腺(HPA)轴功能。
本研究于2021年5月至10月在一家大学医院进行。新冠病毒感染康复三个月后的患者被纳入研究组,选取未感染新冠病毒且特征相似的参与者作为对照组。于上午8点采集血样。使用1μg促肾上腺皮质激素(合成促肾上腺皮质激素)进行肾上腺刺激试验。
研究组包括50例患者,对照组为49例。50例患者中有1例(2%)上午8点血清皮质醇低于5μg/dL。患者组中有7例(14%)参与者检测到低血清促肾上腺皮质激素水平。对50例血清皮质醇低于10μg/dL的患者中的2例(4%)进行了使用1μg促肾上腺皮质激素(合成促肾上腺皮质激素)的刺激试验。两名患者在刺激后皮质醇峰值均超过12.5μg/dL。7例(14%)患者的胰岛素样生长因子 -1(IGF-1)标准差(SD)评分低于年龄和性别的 -2 SD。5例(10%)患者促甲状腺激素水平轻度升高。研究组和对照组的基线垂体激素水平无显著差异。
在经历轻度/中度新冠病毒感染的患者中,基础垂体激素水平和HPA轴功能得以保留且功能正常。然而,在本研究中相当数量的患者在新冠病毒感染后出现了明显症状,且这些症状与垂体功能变化无关。